Alan W. Dunton - 11 Dec 2025 Form 4 Insider Report for ORAGENICS INC (OGEN)

Reporting relationship: Director
Issuer ticker: OGEN
Reported as of: 11 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Dec 2025, 16:25:37 UTC
Prior SEC filing: 11 Dec 2025
Next SEC filing: 02 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Alan Dunton

Key filing fact

Alan W. Dunton filed Form 4 for ORAGENICS INC (OGEN) on 15 Dec 2025.

Key facts

This page summarizes Alan W. Dunton's Form 4 filing for ORAGENICS INC (OGEN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Dec 2025, 16:25.

Change

Previous filing in this sequence was filed on 11 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001304773 Primary reporting owner

DUNTON ALAN W

Relationship: Director
Address: 1990 MAIN STREET, SUITE 750, SARASOTA
Signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Alan Dunton
Signature date: 15 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OGEN transaction Derivative

Non-Employee Director Option (Right to Buy)

Award

Transaction value: $0
Shares: +125,000
Change %
Price: $0.000000
Shares after: 125,000
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $0.9300
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.